Page 127 - Bioterrorism

126

methodology of clinical research, pharmacovigilance, biostatistics,
clinical data management and vaccine production. The second year of
the course will focus on applying the skills acquired during the
program in vaccine research and development programs.

- read the press release
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,l1vg,8qei,4h4n,gyv>

Read more about: university partnership
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,gzya,cqag,4h4n,gyv>
, Novartis
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,hhjp,dgzb,4h4n,gyv>

GlaxoSmithKline unveils $600M vaccine plant
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,grl,iqct,4h4n,gyv>

By John Carroll

<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,9qzx,4zxt,4h4n,gyv#comment>
Comment
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,9qzx,4zxt,4h4n,gyv#comment>
|
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,6rxd,4d96,4h4n,gyv>
Forward
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,6rxd,4d96,4h4n,gyv>

GlaxoSmithKline has taken the wraps off its new, $600 million
vaccine manufacturing plant in Singapore, which will produce jabs for
a range of childhood diseases such as meningitis, pneumonia and blood
poisoning. And the opening ceremony featured plenty of boasting. Glaxo
chief Andrew Witty called the plant "possibly the best vaccine
facility anywhere in the world."

Finishing the plant and getting started actually producing advanced
vaccines, though, are two different things. Production work will only
begin in 2011, giving regulators from the FDA and the World Health
Organization time to inspect the facility. Glaxo used the opening day
ceremony to announce a $30 million fund to endow graduate studies in
manufacturing processes, green chemistry and health policies.

Singapore has pushed hard to expand its biopharma industry and a
number of multinationals have set up operations in the city-state. And
GlaxoSmithKline has been a big supporter. The pharma giant has been
rapidly building its global vaccine business, which was on display
earlier this week with the announcement that GSK is investing $34
million into a new joint venture
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,h66o,5yna,4h4n,gyv>
to produce vaccines in China.

- read the report
<http://www.uptilt.com/c.html?rtr=on&s=69l,176sg,29k4,6un9,am25,4h4n,gyv>
from the Straits Times

Related Articles: